The molecular and cellular mechanisms responsible for cytotoxic T lymphocyte (CTL)-induced immunopathology are not well defined. Using a model in which hepatitis B surface antigen (HBsAg)-specific CTL cause an acute necroinflammatory liver disease in HBsAg transgenic mice, we demonstrate that class I-restricted disease pathogenesis is an orderly, multistep process that involves direct as well as indirect consequences of CTL activation. It begins (step 1) almost immediately as a direct antigen-specific CTL-target cell interaction that triggers the HBsAg-positive hepatocyte to undergo programmed cell death (apoptosis). It progresses (step 2) within hours to a focal inflammatory response in which antigen-nonspecific lymphocytes and neutrophils amplify the local cytopathic effect of the CTL. The most destructive pathogenetic function of the CTL, however, is to secrete interferon gamma when they encounter antigen in vivo, thereby activating the intrahepatic macrophage and inducing a delayed-type hypersensitivity response (step 3) that destroys the liver and kills the mouse. We propose that the principles illustrated in this study are generally applicable to other models of class I-restricted, CTL-induced immunopathology, and we suggest that they contribute to the immunopathogenesis of viral hepatitis during hepatitis B virus infection in humans.
Skip Nav Destination
Article navigation
1 November 1993
Article|
November 01 1993
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.
K Ando,
K Ando
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
T Moriyama,
T Moriyama
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
L G Guidotti,
L G Guidotti
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
S Wirth,
S Wirth
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
R D Schreiber,
R D Schreiber
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
H J Schlicht,
H J Schlicht
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
S N Huang,
S N Huang
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
F V Chisari
F V Chisari
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Search for other works by this author on:
K Ando
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
T Moriyama
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
L G Guidotti
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
S Wirth
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
R D Schreiber
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
H J Schlicht
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
S N Huang
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
F V Chisari
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1993) 178 (5): 1541–1554.
Citation
K Ando, T Moriyama, L G Guidotti, S Wirth, R D Schreiber, H J Schlicht, S N Huang, F V Chisari; Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.. J Exp Med 1 November 1993; 178 (5): 1541–1554. doi: https://doi.org/10.1084/jem.178.5.1541
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement